Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
David Liew drdavidliew
2 years 11 months ago
Can you put a bit of morphine intraarticularly inside an osteoarthritic knee and make it better?
Cute idea, no bingo.
I get that we're chasing better symptomatic solutions, but...
Don't do this.
ABST1833 #ACR22 @RheumNow https://t.co/pvsGx93eoU
David Liew drdavidliew
2 years 11 months ago
Erosive OA:
have we got anything disease-modifying?
Not much right now (read: nothing)
Denosumab 60mg q3mo for bone remodelling?
radiographic change, erosive jt development: real improvement
pain, function: zip at 48w, some at 96w?
Def worth more study!
ABSTL05 #ACR22 @RheumNow https://t.co/Yo9u5BlYYJ
Patricia Harkins DrTrishHarkins
2 years 11 months ago
PAN relapse risk ⬆️ in:
👉severe GI involvement
🧓>65y/o
👉skin necrotic lesions
PAN ⬆️ mortality wt:
👉AKI
🧓>65y/o
👉necrotic purpura
👉secondary PAN
Abst#2232 @RheumNow #ACR22
Akhil Sood MD AkhilSoodMD
2 years 11 months ago
Abstr #2196- COVID-19 outcomes in IMID dx in large US Hospital
vs Pre-Omicron
- ↑ COVID + rate (21.9% vs 7.9%)
- ↓ hospitalized (0.8% vs 3%) & death (1.8% vs 4.5%)
- Hospitalization & death > gen pop both pd.
-Age & comorbidities assoc w worse outcomes
@RheumNow #ACR22
David Liew drdavidliew
2 years 11 months ago
Biosimilar multi-switching in RA: is it an issue?
Switching back & forth between originator & biosimilar should create ideal conditions for immunogenicity or anti-drug Ab
This study: multi-switching vs no switching
No issues at all
Switch away in RA!
ABST1589 #ACR22 @RheumNow https://t.co/pGBF2BHp7y
Dr. John Cush RheumNow
2 years 11 months ago
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/ygfYol5Z3f
Dr. John Cush RheumNow
2 years 11 months ago
ACR2022 Topic Panels https://t.co/5gMfFS8maR
The last day was jammed with important reports and research including the late breaking abstracts.
Curcumin, the active constituent of turmeric extract, has increasingly been promoted as a potential rheumatoid arthritis therapy, but data presented at ACR22 suggests that even in ideal situations, it is unable to do any better than placebo in replacing conventional RA therapies.
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
David Liew drdavidliew
2 years 11 months ago
@rheumecraig @RheumNow Absolutely. In this #ACR22 study, they did exclude anyone with deranged LFTs from this study and yet still two people in the turmeric arm got LFT derangement (vs zero in placebo). Sadly I don't think the turmeric salespeople are watching the LFTs.
Akhil Sood MD AkhilSoodMD
2 years 11 months ago
Abstr #2191 studies impact of maternal SLE on outcomes of children
Maternal SLE assoc w/ ↑ odds of
- SLE of children (HR 98.48, 95%CI:63.39-152.98)
- other AutoImm dx (HR 1.26, 1.02-1.57) (Hashimoto, JRA, IBD)
- Neurodev dx (1.35, 95%CI:1.15-1.57) (ADHD)
@RheumNow #ACR22
Dr. Rachel Tate uptoTate
2 years 11 months ago
UPA tx in prior TNFi tx PsA pts demonstrated consistent efficacy compared to the overall population in SELECT-PsA 2, regardless of number of prior anti-TNF therapies. Abs 2146 #ACR22 @RheumNow https://t.co/xnN4nvZ934 https://t.co/3S6ZzPvqVe
sheila RHEUMarampa
2 years 11 months ago
How to adjust for GC correction when dose >/= 7.5mg/d using FRAX?
Calculate FRAX then
🦴For MOF risk multiply by 1.15
🦴HF risk multiply by 1.2
= adjusted risk (%)
(Adjustment of FRAX accdg to GC dose from Kanis et al., OI 2011)
#ACR22 @RheumNow @Rheumarhyme @PhRheumaJr https://t.co/qap1fFhF0h
One of the enduring legacies of ACR 2022 for me will be the emphasis on polymyalgia rheumatica (PMR). Despite being highly inflammatory and relatively common, a remarkable paucity of trials have been run in this space. Read on for a quick PMR-roundup from the meeting!
Poster Hall